144 related articles for article (PubMed ID: 34009323)
41. Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model.
Ara R; Pandor A; Tumur I; Paisley S; Duenas A; Williams R; Rees A; Wilkinson A; Durrington P; Chilcott J
Am J Cardiovasc Drugs; 2008; 8(6):419-27. PubMed ID: 19159125
[TBL] [Abstract][Full Text] [Related]
42. Cost-effectiveness of treatment in adults with blood pressure of 130-139/80-89 mmHg and high cardiovascular risk in China: a modelling study.
Li J; Zhao D; Cai J; Chen S; Wu S; Qi Y
Lancet Reg Health West Pac; 2024 Jan; 42():100962. PubMed ID: 38045985
[TBL] [Abstract][Full Text] [Related]
43. Effectiveness and cost-effectiveness of interventions that cause weight loss and reduce the risk of cardiovascular disease.
Zomer E; Leach R; Trimmer C; Lobstein T; Morris S; James WP; Finer N
Diabetes Obes Metab; 2017 Jan; 19(1):118-124. PubMed ID: 27649286
[TBL] [Abstract][Full Text] [Related]
44. Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model.
Pufulete M; Maishman R; Dabner L; Mohiuddin S; Hollingworth W; Rogers CA; Higgins J; Dayer M; Macleod J; Purdy S; McDonagh T; Nightingale A; Williams R; Reeves BC
Health Technol Assess; 2017 Aug; 21(40):1-150. PubMed ID: 28774374
[TBL] [Abstract][Full Text] [Related]
45. A multicentre randomised controlled trial and economic evaluation of continuous positive airway pressure for the treatment of obstructive sleep apnoea syndrome in older people: PREDICT.
McMillan A; Bratton DJ; Faria R; Laskawiec-Szkonter M; Griffin S; Davies RJ; Nunn AJ; Stradling JR; Riha RL; Morrell MJ
Health Technol Assess; 2015 Jun; 19(40):1-188. PubMed ID: 26063688
[TBL] [Abstract][Full Text] [Related]
46. Who needs laboratories and who needs statins?: comparative and cost-effectiveness analyses of non-laboratory-based, laboratory-based, and staged primary cardiovascular disease screening guidelines.
Pandya A; Weinstein MC; Salomon JA; Cutler D; Gaziano TA
Circ Cardiovasc Qual Outcomes; 2014 Jan; 7(1):25-32. PubMed ID: 24425701
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece.
Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsimihodimos V; Diogo V; Karpouzos G; Papageorgiou G; Kourlaba G
Clin Drug Investig; 2021 Apr; 41(4):371-380. PubMed ID: 33687695
[TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease.
Stam-Slob MC; van der Graaf Y; de Boer A; Greving JP; Visseren FLJ
Int J Cardiol; 2018 Feb; 253():148-154. PubMed ID: 29306457
[TBL] [Abstract][Full Text] [Related]
49. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
Liew D; Park HJ; Ko SK
Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
[TBL] [Abstract][Full Text] [Related]
50. Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand.
Kongpakwattana K; Ademi Z; Chaiyasothi T; Nathisuwan S; Zomer E; Liew D; Chaiyakunapruk N
Pharmacoeconomics; 2019 Oct; 37(10):1277-1286. PubMed ID: 31243736
[TBL] [Abstract][Full Text] [Related]
51. Offering a lifestyle intervention to women of premenopausal age as primary prevention for cardiovascular disease? - assessing its cost-effectiveness.
Gao L; Moodie M
Int J Behav Nutr Phys Act; 2022 Dec; 19(1):152. PubMed ID: 36517831
[TBL] [Abstract][Full Text] [Related]
52. Cost-Effectiveness of Statin Plus Eicosapentaenoic Acid Combination Therapy for Cardiovascular Disease Prevention in Japanese Patients With Hypercholesterolemia - An Analysis Based on the Japan Eicosapentaenoic Acid Lipid Intervention Study (JELIS).
Kodera S; Morita H; Kiyosue A; Ando J; Komuro I
Circ J; 2018 Mar; 82(4):1076-1082. PubMed ID: 29367520
[TBL] [Abstract][Full Text] [Related]
53. Cost-effectiveness of implementing risk-based cardiovascular disease (CVD) management using updated WHO CVD risk prediction charts in India.
Sivanantham P; S MK; Essakky S; Singh M; Ghosh S; Mehndiratta A; Kar SS
PLoS One; 2023; 18(8):e0285542. PubMed ID: 37624838
[TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.
Schlackow I; Kent S; Herrington W; Emberson J; Haynes R; Reith C; Collins R; Landray MJ; Gray A; Baigent C; Mihaylova B;
Kidney Int; 2019 Jul; 96(1):170-179. PubMed ID: 31005271
[TBL] [Abstract][Full Text] [Related]
55. Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly.
Lin L; Teng M; Zhao YJ; Khoo AL; Seet RC; Yong QW; Yeo TC; Lim BP
Cardiovasc Drugs Ther; 2015 Apr; 29(2):187-97. PubMed ID: 25860556
[TBL] [Abstract][Full Text] [Related]
56. Cost-effectiveness of risk stratified medication management for reducing premature cardiovascular mortality in Kenya.
Subramanian S; Hilscher R; Gakunga R; Munoz B; Ogola E
PLoS One; 2019; 14(6):e0218256. PubMed ID: 31237910
[TBL] [Abstract][Full Text] [Related]
57. Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Health Technology Assessment.
Health Quality Ontario
Ont Health Technol Assess Ser; 2019; 19(6):1-199. PubMed ID: 30873251
[TBL] [Abstract][Full Text] [Related]
58. Do different methods of modeling statin treatment effectiveness influence the optimal decision?
van Kempen BJ; Ferket BS; Hofman A; Spronk S; Steyerberg E; Hunink MG
Med Decis Making; 2012; 32(3):507-16. PubMed ID: 22472915
[TBL] [Abstract][Full Text] [Related]
59. Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study.
Li C; Chen K; Cornelius V; Tomeny E; Wang Y; Yang X; Yuan X; Qin R; Yu D; Wu Z; Wang D; Chen T
PLoS Med; 2021 Mar; 18(3):e1003515. PubMed ID: 33661907
[TBL] [Abstract][Full Text] [Related]
60. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.
Singh K; Crossan C; Laba TL; Roy A; Hayes A; Salam A; Jan S; Lord J; Tandon N; Rodgers A; Patel A; Thom S; Prabhakaran D
Int J Cardiol; 2018 Jul; 262():71-78. PubMed ID: 29622506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
